Lucid Diagnostics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Lucid Diagnostics reported 2,871 tests sold in the 3rd quarter, with a billable value of approximately $7.9 million and recognized revenue of $1.2 million.
- Test volume was up about 4% sequentially and about 1% over last year's 3rd quarter; revenue was essentially flat with last year's 3rd quarter and down from $1.5 million in the 2nd quarter.
- The sequential revenue decline was almost entirely driven by direct contract tests falling from 517 in the 2nd quarter to 60 in the 3rd quarter, which management attributed mostly to event timing.
- Revenue per test was $446 year to date against $383 for all of '25, a 17% improvement; 3rd quarter revenue per test was $419.
- Medicare tests represented about 16% of 3rd quarter volume, or about 450 tests; in October, the team achieved nearly 70% of that Medicare volume and more than 1,800 tests overall, a record monthly level.
- Third-quarter total operating expenses were $13.5 million, down approximately 6% from $14.3 million in the second quarter; non-GAAP operating expenses were $11.8 million versus $12.3 million.
- Third-quarter non-GAAP net loss per share was $0.06, level with the second quarter; GAAP loss per share was $0.03 versus $0.08 last quarter, benefiting from a noncash fair value gain.
- Cash at September 30th was $18 million; after the October 21st closing of a $15 million Series C convertible preferred offering, pro forma cash was approximately $33 million.
- Quarterly burn was $10.2 million, the lowest of the last 4 quarters; average burn for the last 4 quarters, including cash interest on debt, was $11.6 million per quarter.
- The Series C consisted of 15,000 shares at a stated value of $1,000 per share for gross proceeds of $15 million; its conversion price was just over $0.35, and its 20% annual dividend is payable in stock, not cash.
- As of September 30th, GAAP shares outstanding were 191 million; on a current basis, including unvested restricted stock awards and 3.6 million shares issued out of advance in October, the figure was approximately 207 million.
- Lucid said it had performed more than 50,000 eCiguard tests since inception, reflecting more than $140 million in billings against approximately $16 million collected to date.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the Lucid Diagnostics Third Quarter 2026 Business Update Conference Call. Please note, this event is being recorded. I would now like to turn the conference over to Matt Riley, Lucid Diagnostics Vice President of Investor Relations.
Please go ahead. Thank you, operator, and good morning, everyone.
Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and Chief Executive Officer of Lucid Diagnostics, along with Dennis McGrath, Chief Financial Officer of Lucid. The press release announcing our business update and financial results is available on Lucid's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update, press release, and conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the SEC.
For a list and a description of these and other important risks and uncertainties that may affect future operations, see Part 1, Item 1A, entitled Risk Factors in Lucid's most recent annual report on Forms 10-K filed with the SEC, and any subsequent updates filed on the quarterly reports on Forms 10-Q and subsequent Forms 8-K. Except as required by law, Lucid disclaims any intentions or obligations to publicly update or revise any forward-looking statements to reflect changes in expectations or in events, conditions, or circumstances on which the expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. I would now like to turn the call over to Dr. Lishan Aklog, Chairman and CEO of Lucid.
Lishan. Thank you, Matt, and good morning, everyone.
Thank you all for joining us today and for your continued engagement and support. Last month, we announced a major breakthrough for Lucid. We announced that Medicare is now paying for EsoGuard. We believe this breakthrough represents a truly seminal moment in our mission to end the scourge of esophageal cancer. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to our groundbreaking EsoGuard test. With this breakthrough, Lucid now enters a new and exciting chapter focused on commercial acceleration and revenue growth. For the first time, our pursuit of the massive clinical and commercial opportunity that EsoGuard represents will be mostly unconstrained by external factors, and it will depend almost entirely moving forward on our team's commercial and operational execution.
As we'll discuss in more detail, we're only a few weeks into this new chapter, but so far, things are going very well. Let's flesh out some of the details of how we got here, our updated commercial strategy, and expectations for the fourth quarter and the new year. First, though, let's do a little bit of a primer on Medicare coverage. Medicare claims for laboratory tests are adjudicated and paid by the Medicare Administrative Contractor, or MAC, with jurisdiction where the laboratory is located. Medicare's statutory standard for coverage and payment is reasonable and necessary, so a test must be reasonable and necessary for a claim to be paid. Our Texas laboratory is in the Novitas MAC jurisdiction, and this MAC operates outside of the MolDX program. The adjudication and payment of claims submitted by this lab to the MAC is not dependent on the pending MolDX LCD.
Late this summer, we introduced EsoGuard to the Novitas MAC during a productive meeting with its medical directors, and we informed them of our intent to begin submitting claims from the Texas laboratory. Following the meeting, at their request, we submitted an extensive dossier. The dossier included our clinical evidence package and supporting documentation, the manuscripts, the guidelines, and so forth. The dossier incorporated their constructive feedback from the meeting. They acknowledged receipt and completed their review with no additional feedback. We therefore began submitting Medicare claims in late September and began receiving payments shortly thereafter. We have been consistently paid on Medicare claims ever since. So, what does this mean in terms of EsoGuard coverage? It means that the MAC with jurisdiction over our laboratory has reviewed our clinical evidence and the professional society guidelines, and it has adjudicated our Medicare claims as reasonable and necessary.
It also means that EsoGuard claims now have Medicare coverage through claim-by-claim adjudication. The term coverage through claim-by-claim adjudication is a formal CMS term, and it is worth noting, many people don't realize this, that the majority of all Medicare claims have their coverage determination through the same claim-by-claim adjudication process. What does this mean for the pending MolDX LCD? EsoGuard coverage through claim-by-claim adjudication by this MAC is completely independent of the MolDX LCD process. As we'll discuss later, we remain engaged with CMS and are confident that the draft LCD will be published, it'll complete the public comment process, and become final and effective. What does this mean for our commercial trajectory?
What's important to understand and what makes this a true breakthrough is that this coverage pathway allows us to immediately accelerate commercialization, so we no longer have to wait for the MolDX LCD to become final and effective to do so. In effect, what has been a marathon is really now a sprint. As we'll discuss in more detail, we're moving quickly to leverage this EsoGuard Medicare coverage to accelerate commercialization nationwide. Let's dive a bit deeper on commercial execution, starting with our target population and this commercial transition. As a reminder, the at-risk population for EsoGuard testing consists of approximately 30 million patients who are recommended for esophageal pre-cancer testing by professional society guidelines. We know that approximately 50% of these 30 million patients are of Medicare age.
Approximately 10%-15% of the over 50,000 EsoGuard tests that have been performed to date have been on Medicare beneficiaries. With EsoGuard now fully reimbursed by Medicare, we can now seek to offer this test much more broadly to the entire at-risk Medicare population. With Medicare reimbursement secured, we immediately and aggressively transitioned our commercial activity to focus on access to EsoGuard in the Medicare population. We have already implemented numerous changes to our commercial efforts, focused on patient identification and partnering with local physicians. These include geographic positioning of our sales and clinical resources, updated comp plans, data-driven routing, and a number of creative programs to find and engage with at-risk Medicare patients. Really excited to report that these efforts are very quickly bearing fruit. Just six weeks into the transition, we are seeing very strong early momentum.
Our messaging with providers on the importance of offering EsoGuard testing to their Medicare patients is resonating. They get it. These patients are at higher risk and will benefit the most from esophageal pre-cancer testing. The patients also get it. We educate them that heartburn can lead to cancer and on the value of our simple one- to two-minute office pre-cancer test. October was a record month for test volume. The team is now laser-focused on converting this great start into a really strong quarter. Over the past six weeks, Dennis, Matt, and I have frequently been asked whether our growth is limited by capacity in any way. It is not. We have plenty of lab capacity, including at our Texas lab, and that capacity is scalable with short lead times. The same applies to our manufacturing capacity for both EsoCheck and the EsoGuard collection kits.
Our clinical specialist team is also well-positioned to support this transition, and they can scale as needed. Thanks to our recent $50 million financing, we believe we have sufficient runway to drive commercial acceleration and revenue growth. The next most common question that we are asked is, "How fast can you scale commercial activity to take advantage of this significant revenue opportunity?" I think the answer to that is that we plan to be aggressive but responsible. Dennis will dive in a bit deeper on the near-term revenue opportunity simply based on closing the realization gap at our current level of activity. In terms of our sales infrastructure, we currently have approximately 30 sellers in the field, and we are confident that we can drive near-term growth by driving productivity through the efforts we have already implemented in the past few weeks.
Future sales infrastructure growth will be responsibly calibrated based on the near-term revenue trajectory that we see. Let us now move on to a broader update on other aspects of our business. Starting with CMS and the MolDX LCD. As I mentioned, we continue to wait for publication of the draft MolDX LCD. We remain engaged with CMS on the status of this LCD, given the persistent backlog of MolDX LCDs. We held a formal meeting with CMS leadership this past quarter to discuss our pending MolDX LCD request for reconsideration, and based on that meeting, we remain confident that the draft LCD will be published when the backlog begins to clear and that it will complete the public comment period and become final and effective. We also announced two important billing and coding milestones. A new Category III CPT code for EsoCheck cell collection was approved.
This code plays an important role in our ongoing engagement with health systems. A new ICD-10 diagnosis code linked to a positive EsoGuard test was also issued. The ICD-10 code gives physicians a dedicated way to document the need for follow-up endoscopy after a positive EsoGuard result. These may seem a bit mundane compared to Medicare reimbursement, but they serve a very important role, making EsoGuard and EsoCheck easier to bill and track and integrate into clinical practice. Turning to commercial coverage. Our focus on Medicare reimbursement and commercialization has in no way detracted from our parallel efforts on the commercial coverage front. The Concert Laboratory Benefit Manager EsoGuard coverage policy that we announced last quarter is bearing fruit. We expect by the end of the year to have a total of five Concert client plans that have formally adopted it, including the three that we previously reported last quarter.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
